NewAmsterdam Pharma Company NV
NAMS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.64B
Close$
$2.92
89.1% downside
Current Fair Value
89.1% downsideOvervalued by 89.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.64 Billion |
|---|---|
| Enterprise Value | $3.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.11 |
| Outstanding Shares | 123,370,232 |
Return
| Return on Equity | -41.10% |
|---|---|
| Return on Assets | -36.84% |
| Return on Invested Capital | -40.57% |
Valuation & Multiples
| P/E Ratio | -12.83 |
|---|---|
| PEG | -4.76 |
| Price to Sales | - |
| Price to Book Ratio | 5.33 |
| Enterprise Value to Revenue | 452.31 |
| Enterprise Value to EBIT | -12.57 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$2.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$7.54 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 184.26% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.61%▼ 99.45% |
|---|---|
| Total Invested | $353.09M▼ 91.09% |
| Investors Holding | 67▼ 114.00% |
ESG Score
No data